Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Enlaza Therapeutics is developing protein-based therapeutics that bind irreversibly to their target.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. Nat. Rev. Drug Discov. https://doi.org/10.1038/nrd3410 (2011).
Naim, N., Moukheiber, S., Daou, S. & Kourie, H. R. Crit. Rev. Oncol. Hematol. https://doi.org/10.1016/j.critrevonc.2021.103524 (2021).
Li, Q. et al. Cell https://doi.org/10.1016/j.cell.2020.05.028 (2020).
Klauser, P. C. et al. ACS Cent. Sci. https://doi.org/10.1021/acscentsci.3c00288 (2023).
Yu, B. et al. Chem https://doi.org/10.1016/j.chempr.2022.07.012 (2022).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M. Editor’s pick: Enlaza Therapeutics. Nat Biotechnol 43, 1591–1592 (2025). https://doi.org/10.1038/s41587-025-02831-5
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02831-5
